Date:6/17/2011

and timing of possible regulatory approval and commercial launch of Regeneron's late-stage product candidates, determinations by regulatory and administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize its product and drug candidates, competing drugs that may be superior to Regeneron's product and drug candidates, uncertainty of market acceptance of Regeneron's product and drug candidates, unanticipated expenses, the availability and cost of capital, the costs of developing, producing, and selling products, the potential for any license or collaboration agreement, including Regeneron's agreements with Sanofi and Bayer HealthCare, to be canceled or terminated without any product success, and risks associated with third party intellectual property and pending or future litigation relating thereto.  A more complete description of these and other material risks can be found in Regeneron's filings with the United States Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2010 and Form 10-Q for the quarter ended March 31, 2011.  Regeneron does not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise, unless required by law.Contact Information:Michael Aberman, M.D.

Peter DworkinInvestor Relations

Corporate Communications914.345.7799

914.345.7640michael.aberman@regeneron.com

peter.dworkin@regeneron.com
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Shenzhen Wuzhou Changlian International Trading Co. Establishes Relationship with Hospital in Africa
2. Shenzhen Wuzhou Changlian International Trading Co. Announces Arrival of New Infrared Thermometer Series
3. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
4. Internal Fixation Systems, Inc. Announces Form S-1 Declared Effective by SEC and Anticipated Quotation for Trading on OTCQB
5. InspireMD to Commence Trading as a Public Company Under Ticker Symbol "NSPR"
6. Trading Halted Today in Optimer Pharmaceuticals Stock
7. Milestone Scientific Inc. Commences Trading on the OTC Pink
8. ERT to Change Trading Symbol to "ERT" Effective March 7, 2011 to Properly Align Business Brand
9. SCOLR Pharma, Inc. Common Stock to Begin Trading on OTC Bulletin Board and OTCQB Stock Market on January 13, 2011
10. BioDrain Medical, Inc. Is Eligible for Trading on the OTCBB, Notice of Allowance on Canadian Patent Application
11. China PharmaHub Corp. Begins Trading Under Stock Symbol CPHB Instead of WRLC